The therapeutic utility of CAR-engineered NK cells for the treatment of glioblastoma has so far mainly been investigated in preclinical studies with effector cells targeting EGFRvIII, EGFR or ErbB2 (Table 1). The gene discussed is EGFR; the disease is glioblastoma.